Opinion|Videos|May 17, 2024

KEYNOTE-564: Adjuvant Pembrolizumab in Renal Cell Carcinoma

Dr Pal discusses the study design and results of the KEYNOTE-564 trial, and Benjamin Gerendash, MSN, RN, AGACNP-BC, discusses the management of adverse events associated with pembrolizumab.


Latest CME